#United States #New York #Pomerantz LLP #argenx SE #FDA Alert

Overview

Pomerantz LLP, a prominent law firm known for its advocacy on behalf of investors, has initiated an investigation concerning potential claims from investors of argenx SE, a biopharmaceutical company listed on NASDAQ under the ticker ARGX. This comes after significant concerns arose pertaining to the safety of one of its key products, Vyvgart Hytrulo. On June 30, 2025, the U.S. Food and Drug Administration (FDA) released a troubling alert that warned of serious risks tied to the medication, which raised alarm bells and led to a notable decline in the company's stock price.

The FDA Alert

The FDA’s alert pointed to a potential association between Vyvgart Hytrulo and severe adverse effects, particularly emphasizing the risk of exacerbating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The warning was based on reports collected through the FDA’s Adverse Event Reporting System, which flagged alarming occurrences that could signify deeper systemic issues with the drug. This kind of governmental scrutiny often serves as an early warning sign that further investigations into a company's practices and product safety protocols are warranted. The FDA also mentioned that it is actively assessing the necessity for regulatory action against argenx.

Market Reaction

In response to the FDA alert, argenx’s American Depositary Shares (ADS) experienced a notable decline, dropping by $8.92, or 1.59%, to settle at $551.22 per share by the close of trading on June 30. Such a reaction from the market underscores the impact that regulatory alerts can have on investor confidence and market valuations, particularly in sectors like biotech, where product safety is paramount.

Pomerantz's Role

Pomerantz LLP has established itself as a respected entity in the field of securities class action litigation, founded by trailblazer Abraham L. Pomerantz. With a rich legacy spanning over 85 years, the firm continues to champion the rights of shareholders and has successfully recovered significant damages for investors in various high-profile cases of securities fraud and corporate misconduct. Their current investigation aims to determine if argenx, along with its executives, may have engaged in deceptive practices that misled investors regarding the safety and efficacy of its treatments.

Call to Action for Investors

Investors who have encountered financial losses as a result of their investments in argenx SE are encouraged to come forward and participate in the investigation led by Pomerantz. The firm is inviting affected investors to reach out to Danielle Peyton at [email protected] or by phone at 646-581-9980, ext. 7980. The potential collective nature of this investigation suggests that there may be a class action lawsuit in the works, providing a legal avenue for those impacted.

Conclusion

As the investigation unfolds, it will be essential for stakeholders to remain vigilant and monitor updates related to both the FDA’s assessments and any developments from the Pomerantz Law Firm. The implications of this case could resonate through the biotech sector, affecting not just argenx but potentially influencing regulatory practices and investor trust within the industry. Investors are reminded that past results do not assure similar outcomes, and the landscape of securities litigation can change rapidly based on new information and market conditions.